Notice of Annual General Meeting/Proxy Form
Released
Released
Announcement PDF
ABN 16 165 160 841
Amplia Therapeutics Limited
ACN 165 160 841
Notice of Annual General Meeting
and Explanatory Statement
2024 Annual Report:
https://www.ampliatx.com/investor-information/reports/annual-reports
THIS IS AN IMPORTANT DOCUMENT
AND REQUIRES YOUR ATTENTION
This Notice of Meeting and the accompanying Explanatory Memorandum
should be read in their entirety.
If, as a shareholder, you are in doubt as to the course you should follow,
please consult your financial or professional adviser prior to voting.
NOTICE is given that the annual general meeting (AGM) of Amplia
Therapeutics Limited (the Company) will be held at Grant Thornton, Collins
Square, Level 22, Tower 5, 727 Collins Street, Melbourne Victoria Australia at
10.30am on Friday 23 August 2024.
ITEMS OF BUSINESS
Item 1. Receipt of the Financial Report for the year ended 31 March 2024
Receipt of the Company's Financial Report, the Directors' Report and the Auditor's Report for
the year ended 31 March 2024.
Resolution 1 – Remuneration Report
To consider and, if thought fit, pass the following resolution as an ordinary resolution:
“That, for the purposes of section 250R(2) of the Corporations Act and for all other purposes,
the Remuneration Report for the year ended 31 March 2024 be adopted.”
Note: A voting exclusion applies to this Resolution.
Resolution 2 – Re-elect Dr Robert Peach as a Director of the Company
To consider and, if thought fit, pass the following resolution as an ordinary resolution:
“That Dr Robert Peach, who retires in accordance with the Constitution of the Company
and, being eligible, offers himself for re-election, be re-elected as a Director of the
Company.”
Resolution 3 – Re-elect Ms Jane Bell as a Director of the Company
To consider and, if thought fit, pass the following resolution as an ordinary resolution:
“That Ms Jane Bell, who retires in accordance with the Constitution of the Company and,
being eligible, offers herself for re-election, be re-elected as a Director of the Company.”
Resolution 4 – Proposed Issue of Shares to Dr Christopher Burns (Managing Director and
Chief Executive Officer)
To consider, and if thought fit, to pass the following resolution as an ordinary resolution:
“That the issue of 586,321 Shares to Dr Christopher Burns (or his nominee), details of
which are set out in the Explanatory Statement, is approved under and for the purpose of
Listing Rule 10.14 and for all other purposes.”
Note: A voting exclusion applies to this Resolution.
Resolution 5 – Ratify the Previous Issue of 3,500,000 Options
To consider and, if thought fit, pass the following resolution as an ordinary resolution:
“That for the purposes of Listing Rule 7.4 and for all other purposes, the Company
approves and ratifies the issue of 3,500,000 Options in the Company issued on the terms
and conditions set out in the accompanying Explanatory Memorandum.”
Note: A voting exclusion applies to this Resolution.
Resolution 6 – Approval for extra 10% Placement Facility
To consider and, if thought fit, to pass the following resolution as a special resolution:
“That the Company have the additional capacity to issue equity securities provided for in
Listing Rule 7.1A.”
ATX - Notice of 2024 Annual General Meeting FINAL
2
VOTING EXCLUSIONS
Corporations Act
Resolution
Resolutions 1
Remuneration Report
Person excluded or prohibited from voting
The Company will disregard votes cast by a member of the Key
Management Personnel of the Company details of whose
remuneration are included in the Remuneration Report, or a
Closely Related Party of such a member, in contravention of
section 250R or 250BD of the Corporations Act. Restrictions also
apply to votes cast by such persons as proxy unless the
appointment specifies the way the proxy is to vote on the
resolution and the vote is not cast on behalf of a person that is
prohibited from voting.
Resolutions 4 – Proposed
issue of Shares to Dr Chris
Burns
The Company will disregard votes cast by Key Management
Personnel or their Closely Related Parties in contravention of
section 250BD of the Corporations Act.
Listing Rules
In accordance with the Listing Rule 14.11, the Company will disregard votes cast in favour of the
following resolutions by or on behalf of:
Resolution
Resolution 4 – Proposed
Issue of Shares to Dr
Christopher Burns
Person excluded from voting
Dr Christopher Burns, his nominees(s), any other person who will
obtain a material benefit as a result of the issue of securities in
accordance with this Resolution, any other person referred to in
ASX Listing Rules 10.14.1, 10.14.2 or 10.14.3 who is eligible to
participate in the Company’s Employee Security Ownership Plan
and any of their Associates.
Resolution 5 - Ratify the
Previous Issue of 3,500,000
Options
Taycol Nominees Pty Ltd being the party who participated in the
issue being approved.
However, the Company need not disregard on the above Resolutions if the vote is cast by:
(a)
(b)
(c)
a person as proxy or attorney for a person who is entitled to vote on the Resolution, in
accordance with the directions given to the proxy or attorney to vote on the Resolution
in that way; or
the person chairing the Meeting as proxy or attorney for a person who is entitled to
vote on the resolution, in accordance with the direction given to the chair to vote as
the chair decides; or
a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on
behalf of a beneficiary provided the following conditions are met:
•
the beneficiary provides written confirmation to the holder that the beneficiary
is not excluded from voting, and is not an Associate of a person excluded from
voting, on the Resolution; and
•
the holder votes on the Resolution in accordance with the directions given by
the beneficiary to the holder to vote in that way.
Dated the 12th day of July 2024.
By order of the Board
Andrew J. Cooke
Company Secretary
ATX - Notice of 2024 Annual General Meeting FINAL
3
SHAREHOLDERS WHO ARE ENTITLED TO VOTE
In accordance with regulation 7.11.37 of the Corporations Regulations 2001 (Cth), the
directors have determined that a person’s entitlement to vote at the meeting will be the
entitlement of that person set out in the register of members at 7.00pm on 21 August 2024.
2024 ANNUAL REPORT:
The 2024 Annual Report is available on the Company’s Website: www.ampliatx.com and
https://www.ampliatx.com/investor-information/reports/annual-reports
PROXIES:
•
Shareholders wishing to appoint a proxy are encouraged to do so electronically by following the
steps set out on the Proxy Form attached.
•
A Shareholder entitled to attend and vote at the Meeting is entitled to appoint a proxy or not more
than two proxies to attend and vote instead of the shareholder.
•
Where two proxies are appointed:
(i) a separate Proxy Form, should be used to appoint each proxy;
(ii) the Proxy Form may specify the proportion, or the number, of votes that the proxy may
exercise, and if it does not do so the proxy may exercise half of the votes.
•
A Shareholder can appoint any other person to be their proxy. A proxy need not be a
Shareholder. The proxy appointed can be described in the Proxy Form by an office held e.g.
“the Chair of the Meeting”.
•
In the case of Shareholders who are individuals, the Proxy Form must be signed:
(i) if the Shares are held by one individual, by that Shareholder;
(ii) if the Shares are held in joint names, by any one of them.
•
In the case of Shareholders who are companies, the Proxy Form must be signed:
(i) if it has a sole director who is also sole secretary, by that director (and stating the fact next
to, or under the signature on the Proxy Form);
(ii) in the case of any other company by either two directors or a director and secretary.
The use of the common seal of the company, in addition to those required signatures, is optional.
•
If the person signing the Proxy Form is doing so under a power of attorney, or is an officer of a
company outside those referred to above but authorised to sign the Proxy Form, the power of
attorney or other authorisation (or a certified copy of it), as well as the Proxy form, must be
received by the Company by the time and at the place specified below.
•
A Proxy Form accompanies this notice. To be effective, your Proxy Form must be received by
the Company no later than 48 hours before the time of the Meeting:
(i)
by facsimile : on 1 800 783 447 (within Australia) or +61 3 9473 2555 (from outside of
Australia) ; or
(ii)
by mail :
Computershare Investor Services Pty Limited
GPO Box 242 Melbourne
Victoria 3001 Australia ; or
(iii) Lodge your vote Online : www.investorvote.com.au using the Control Number and your
SRN/HIN which are provided on the front side of your Proxy Form.
(iv) Custodians: Intermediary Online subscribers only, cast the shareholder’s vote online by
visiting www.intermediaryonline.com.
ATX - Notice of 2024 Annual General Meeting FINAL
4
EXPLANATORY STATEMENT
ITEM 1: Financial Report – Year ended 31 March 2024
The Corporations Act requires the Financial Report (which includes the financial statements
and the Directors’ Declaration), the Directors’ Report and the Auditor’s Report to be tabled for
discussion at the AGM. There is no requirement either in the Corporations Act or in the
Constitution for Shareholders to approve the Financial Report, the Directors’ Report or the
Auditor’s Report. Shareholders attending the AGM will be given a reasonable opportunity to
ask questions about, or make comments on, these reports.
This item of business provides Shareholders with an opportunity to ask questions concerning
or make comments on the Company’s financial statements and reports for the financial year
ended 31 March 2024 and the Company’s performance generally.
A representative of the Auditor (Grant Thornton) will be attending the AGM.
As a Shareholder, you are entitled to submit a written question to the Auditor prior to the AGM
provided that the question relates to:
•
•
the content of the Auditor’s Report; or
the conduct of the audit in relation to the Financial Report.
All written questions must be received by the Company no later than 16 August 2024. All
questions must be sent to the Company by email to info@ampliatx.com and may not be sent
direct to the Auditor. The Company will then forward all relevant questions to the Auditor.
The Auditor will answer written questions submitted prior to the AGM.
The Auditor will also answer questions at the meeting from Shareholders relevant to:
•
•
•
•
the conduct of the audit;
the preparation and content of the Auditor’s Report;
the accounting policies adopted by the Company in relation to the preparation of the
financial statements; and
the independence of the Auditor in relation to the conduct of the audit.
RESOLUTION 1: Remuneration Report
The Directors’ Report for the financial year ended 31 March 2024 contains a Remuneration
Report which sets out the policy on remuneration of the Directors of the Company and specified
executives of the Company.
The Corporations Act requires that a resolution be put to the vote that the Remuneration Report
be adopted. The Corporations Act expressly provides that the vote is advisory and does not
bind the Directors of the Company.
Notwithstanding the non-binding nature of the vote, the Directors will take note of the outcome
of the vote when considering future remuneration matters.
Members attending the AGM will be given a reasonable opportunity to ask questions about, or
make comments on, the Remuneration Report.
Under the Corporations Act, if at least 25% of the votes cast on Resolution 1 are against the
adoption of the relevant remuneration report at two consecutive annual general meetings (with
a 25% or more vote 'against' commonly referred to as a "first strike" or "second strike"), the
Company will be required to put to Shareholders a resolution at the later of those annual
general meetings proposing that an extraordinary general meeting (Spill Meeting) be called
ATX - Notice of 2024 Annual General Meeting FINAL
5
to consider the election of directors of the company (Spill Resolution). The Spill Meeting must
be held within 90 days of the date of the second annual general meeting. For a Spill Resolution
to be passed, more than 50% of the votes cast on the resolution must be in favour of it. If a
Spill Resolution is passed, all of the directors (other than any managing director) will cease to
hold office immediately before the end of the Spill Meeting unless re-elected at that meeting.
At the Company’s 2023 Annual General Meeting, a “first strike” was not recorded in respect of
the Remuneration Report. Accordingly, a Spill Resolution is not relevant for this Meeting.
Recommendation
The Directors abstain, in the interests of corporate governance, from making a
recommendation in relation to Resolution 1.
Subject to the voting exclusions set out in the Notice of Meeting, the Chairman of the meeting
intends to vote undirected proxies in favour of Resolution 1.
RE-ELECTION OF DIRECTORS (Resolutions 2 and 3)
ASX Listing Rules 14.4, 14.5 and the Constitution of the Company
ASX Listing Rule 14.4 provides that a director of an entity must not hold office (without reelection) past the third annual general meeting following the director’s appointment or 3 years,
whichever is longer. This rule does not apply to the managing director.
ASX Listing Rule 14.5 provides that an entity which has directors must hold an election of
directors at each annual general meeting.
Under Article 8.1 of the Company’s Constitution:
(c)
A director appointed by the Board under rule 8.1(b), who is not a chief executive officer,
holds office until the conclusion of the next AGM following his or her appointment.
(d)
No director who is not the chief executive officer may hold office without re-election
beyond the third AGM following the meeting at which the director was last elected or
re-elected.
(f)
To the extent that the Listing Rules require an election of directors to be held and no
director would otherwise be required (by rules 8.1(c) or 8.1(d)) to submit for election or
re-election the director to retire is any director who wishes to retire (whether or not he
or she intends to stand for re-election), otherwise it is the director who has been
longest in office since their last election or appointment (excluding the chief executive
officer). As between directors who were last elected or appointed on the same day, the
director to retire must be decided by lot (unless they can agree among themselves).
Out of the current Directors who may be required to retire by rotation, Ms Jane Bell and Dr
Robert Peach have held office for the longest period of time since their last election (which
occurred at the Company’s 2021 AGM on 27 August 2021).
Accordingly, in accordance with Article 8.1 of the Constitution and Listing Rule 14.4, Ms Bell
and Dr Peach retire by rotation and, being eligible, offer themselves for re-election as
Directors.
ATX - Notice of 2024 Annual General Meeting FINAL
6
RESOLUTION 2: Re-election of Dr Robert Peach (PhD) (Independent Non-Executive Director)
Dr Peach has over 30 years of drug discovery and development experience in the
Pharmaceutical and Biotechnology industry. In 2009 he co-founded Receptos, becoming Chief
Scientific Officer and raising $59M in venture capital and $800M in an IPO and three
subsequent follow-on offerings. In August 2015 Receptos was acquired by Celgene for $7.8B.
Dr Peach held senior executive and scientific positions in other companies including Apoptos,
Biogen Idec, IDEC and Bristol-Myers Squibb, supporting in-licensing, acquisition and venture
investments. His extensive drug discovery and development experience in autoimmune and
inflammatory diseases, and cancer has resulted in multiple drugs entering clinical trials and 3
registered drugs. He currently serves on the Board of Directors of ASX-listed AdAlta Limited
(1AD), and Rekover Therapeutics, a privately held biotechnology company in New Zealand.
Dr Peach also serves on the Scientific Advisory Board of privately held Eclipse Bioinnovations
in San Diego and is a consultant for several other biotechnology companies. Dr Peach is the
co-author of 75 scientific publications and book chapters, and is an inventor on 17 patents. He
was educated at the University of Canterbury and the University of Otago, New Zealand.
Dr Peach was appointed as an Independent Non-Executive Director on the 2nd of September
2015 and is Chair of the Remuneration Committee and a member of the Audit and Risk
Committee.
Recommendation
The Directors (other than Dr Peach) recommend that Shareholders vote in favour of
Resolution 2.
The Chairman of the meeting intends to vote undirected proxies in favour of Resolution 2.
RESOLUTION 3: Re-election of Ms Jane Bell AM (BEc LLB LLM (Lond) FAICD)
(Independent Non-Executive Director)
Ms Bell is a banking and finance lawyer and non-executive director with more than 30 years’
experience in leading law firms, financial services and corporate treasury operations gained
living in Melbourne, London, Toronto, San Francisco and Brisbane. Ms Bell has been a nonexecutive director since 2002, serving on 17 boards including public and private hospitals,
biotechnology, medical research and funds management boards. Ms Bell currently serves as
Deputy Chair of Monash Health, Chair of Mesoblast Limited (ASX:MSB)(Nasdaq:MESO) and
Director of Jessie McPherson Private Hospital.
Ms Bell is a former Member of the Administrative Appeals Tribunal and former Chair of
Melbourne Health (Royal Melbourne Hospital), Chair of Biomedical Research Vic, Deputy
Chair of Westernport Water Corporation, Director of U Ethical Funds Management and its
subsidiaries, WorkSafe Victoria, Hudson Institute of Medical Research-Monash Institute of
Medical Research-Prince Henry’s Institute of Medical Research, Queensland Institute of
Medical Research Trust, Australian RedCross (Qld) and Victorian Women’s Housing
Association. Ms Bell holds a Master of Laws from Kings College, London, Bachelor of Laws
from the University of Melbourne, Bachelor of Economics from Monash University and is a
Fellow of the Australian Institute of Company Directors.
In 2023, Ms Bell was appointed a Member of the Order of Australia (AM) for her significant
service to governance in the medical research, healthcare and not for profit sectors.
Ms Bell was appointed as an Independent Non-Executive Director on 12 April 2021 and is
Chair of the Audit and Risk Committee and a member of the Remuneration Committee.
ATX - Notice of 2024 Annual General Meeting FINAL
7
Recommendation
The Directors (other than Ms Bell) recommend that Shareholders vote in favour of
Resolution 3.
The Chairman of the meeting intends to vote undirected proxies in favour of Resolution 3.
4.
RESOLUTION 4 – Proposed issue of Shares to Dr Christopher Burns
4.1
Background
Dr Christopher Burns was appointed as Chief Executive Officer on 5 December 2022.
Following a review of remuneration offered to the executive directors of peer group companies,
the Remuneration Committee determined an appropriate remuneration package for the Chief
Executive Officer. Details of Dr Burns remuneration are set out in section 4.2 iv. of this Notice.
Under his Employment Agreement, Dr Burns is entitled to a bonus incentive of up to 25% of
his Total Fixed Remuneration, payable based on his performance against agreed performance
milestones. The Board has determined that it is more appropriate at the present time to issue
Shares to Dr Burns under the Company’s Employee Security Ownership Plan (the Plan) in lieu
of a cash payment. This serves to incentivise Dr Burns and to increase alignment with
shareholders’ interests and to maximise Company value whilst also preserving the Company’s
cash resources. The Shares will form part of Dr Burns’ remuneration.
ASX Listing Rule 10.14 provides that a company must not permit a director to acquire shares
under an employee incentive scheme without the prior approval of holders of ordinary
securities.
Resolution 4 seeks approval under ASX Listing Rule 10.14 to issue a total of 586,321 Shares
to Dr Burns (the Issue).
Under Chapter 2E of the Corporations Act, for a public company to give a financial benefit to
a related party of the public company, the public company must:
•
obtain the approval of the public company's members in the manner set out in sections
217 to 227 of the Corporations Act; and
•
give the benefit within 15 months following such approval,
unless the giving of the financial benefit falls within an exception set out in sections 210 to 216
of the Corporations Act.
It is the view of the Board (excluding Dr Burns) that the exception set out in section 211(1)
(allowing the giving of a financial benefit that is reasonable remuneration) applies in the current
circumstances. Accordingly, Shareholder approval is sought for the issue of the Shares under
ASX Listing Rule 10.14 as contemplated by Resolution 4, but not under Chapter 2E of the
Corporations Act.
4.2
Specific information required by Listing Rule 10.15
Pursuant to ASX Listing Rule 10.15, the following information is provided in relation to
Resolution 4:
i.
The Shares are to be issued to Dr Christopher Burns (or his nominee).
ii.
Dr Burns is a related party by virtue of being Managing Director and Chief Executive
Officer of the Company which falls within Listing Rule 10.14.1;
ATX - Notice of 2024 Annual General Meeting FINAL
8
iii.
The number of Shares (being the nature of the financial benefit being provided) to be
allocated to Dr Burns is 586,321.
iv.
Dr Burns’ current Total Fixed Remuneration is $350,000 per year inclusive of statutory
superannuation. Dr Burns may also be eligible to receive Long Term Incentives under
the Company’s Plan from time to time subject to Board and shareholder approval. In
addition Dr Burns will be entitled to a bonus incentive of up to 25% of his Total Fixed
Remuneration, which will be payable based on his performance against agreed
performance milestones, which may be paid annually in cash or equity and at the Board’s
discretion and subject to shareholder approval if payable in equity.
v.
The Plan was approved by shareholders at the Company’s Annual General Meeting held
on 25 August 2022. At that meeting shareholders also approved the issue of 535,000
options to Dr Burns for nil consideration. Those options have an exercise price of $0.26
and an expiry date of 6 September 2025. In addition, at the Company’s Annual General
Meeting held on 24 August 2023 shareholders approved the issue of 2,500,000 options
to Dr Burns for nil consideration. Those options have an exercise price of $0.135 and an
expiry date of 5 June 2028
vi.
The securities being issued to Dr Burns are fully paid ordinary Shares which are to be
issued at a deemed issue price of $0.062 being the 5 day VWAP of the Company’s
Shares as at 5 July 2024.
vii.
The Shares will be granted no later than 3 months after the date of the Annual General
Meeting however it is anticipated that the Shares will be issued to Dr Burns shortly after
the date of this meeting if Resolution 4 is approved by shareholders.
viii.
The Shares will be issued to Dr Burns for nil consideration.
ix.
A summary of the material terms of the Plan is set out in Schedule1.
x.
No loan will be made to the Dr Burns in respect of the grant of the Shares.
xi.
The Company confirms that:
xii
•
Details of any securities issued under the Plan will be published in the annual report
of the Company relating to the period in which they were issued, along with a
statement that approval for the issue was obtained under Listing Rule 10.14.
•
Any additional persons covered by Listing Rule 10.14 who become entitled to
participate in an issue of securities under the Plan after Resolution 4 is approved
who were not named in the Notice will not participate until approval is obtained
under that Rule.
A voting exclusion statement in relation to Resolution 4 is included in the Notice.
Resolution 4 seeks shareholder approval to the Issue under and for the purposes of Listing
Rule 10.14.
If resolution 4 is passed, the Company will be able to proceed with the Issue to Dr Burns which
will form part of his remuneration.
If resolution 4 is not passed, the Company will not be able to proceed with the Issue and the
Company will instead be required to pay a cash bonus to Dr Burns which will take away the
incentive value of the proposed Issue to Dr Burns and potentially diminish the expected
alignment with shareholders’ interests. If the Company is required to pay a cash bonus to Dr
Burns rather than effecting the Issue this will have the effect of depleting the Company’s
available cash resources.
ATX - Notice of 2024 Annual General Meeting FINAL
9
4.3
Recommendation
The Directors (other than Dr Burns) recommend that Shareholders vote in favour of Resolution
4.
Subject to the voting exclusions set out in the Notice of Meeting, the Chairman of the meeting
intends to vote undirected proxies in favour of Resolution 4.
RESOLUTION 5: Ratify the Allotment of 3,500,000 Options
As announced to the ASX on 15 May 2024 the Company completed a fully underwritten
entitlement offer (Entitlement Offer) which raised $4.27m. The Company issued 77,602,838
Shares on 15 May 2024 at $0.055 per share pursuant to the Entitlement Offer.
Taylor Collison Limited acted as Lead Manager to the Entitlement Offer.
The proceeds from the Entitlement Offer will be used to fund the ongoing Phase 2 ACCENT
trial in pancreatic cancer to an Interim Analysis (expected in Q3 2024), as well as undertake
production of additional narmafotinib capsules and support a pilot Investigator Initiated trial in
ovarian cancer currently in planning.
On 15 May 2024 the Company also issued 3,500,000 options exercisable at $0.135 with an
expiry date of 5 June 2028 to Taycol Nominees Pty Ltd as part of the agreed fee payable to
the Lead Manager (the Issue). The Issue was made within the Company’s placement capacity
under ASX Listing Rule 7.1.
Broadly speaking, and subject to a number of exceptions, Listing Rule 7.1 limits the amount of
equity securities that a listed company can issue without the approval of its shareholders over
any 12 month period to 15% of the fully paid ordinary securities it had on issue at the start of
that period.
The Issue does not fit within any of these exceptions and, as it has not yet been approved by
the Company’s shareholders, it effectively uses up part of the 15% limit in Listing Rule 7.1,
reducing the Company’s capacity to issue further equity securities without shareholder
approval under Listing Rule 7.1 for the 12 month period following the Issue Date.
Listing Rule 7.4 allows the shareholders of a listed company to approve an issue of equity
securities after it has been made or agreed to be made. If they do, the issue is taken to have
been approved under Listing Rule 7.1 and so does not reduce the company’s capacity to issue
further equity securities without shareholder/unitholder approval under that rule.
The Company wishes to retain as much flexibility as possible to issue additional equity
securities into the future without having to obtain shareholder approval for such issues under
Listing Rule 7.1.
To this end, Resolution 5 seeks shareholder approval to the Issue under and for the purposes
of Listing Rule 7.4.
If Resolution 5 is passed, the Issue will be excluded in calculating the Company’s 15% limit in
Listing Rule 7.1, effectively increasing the number of equity securities it can issue without
shareholder approval over the 12 month period following the Issue Date.
If Resolution 5 is not passed, the Issue will be included in calculating the Company’s 15% limit
in Listing Rule 7.1, effectively decreasing the number of equity securities it can issue without
shareholder approval over the 12 month period following the Issue Date.
ATX - Notice of 2024 Annual General Meeting FINAL
10
RESOLUTION 6 – Approval of Additional 10% Placement Facility
The Company is seeking Shareholder approval by way of a special resolution to have the
ability to issue Equity Securities under the 10% Placement Facility to provide the Company
with additional flexibility to issue Equity Securities in appropriate circumstances. The exact
number of Equity Securities to be issued under the 10% Placement Facility will be determined
in accordance with the formula prescribed in ASX Listing Rule 7.1A.2 (described further below).
ASX Listing Rule 7.1A
Broadly speaking, and subject to a number of exceptions, Listing Rule 7.1 limits the amount of
Equity Securities that a listed company can issue without the approval of its shareholders over
the relevant 12 month period to 15% of the fully paid ordinary securities it had on issue at the
start of that period.
Under Listing Rule 7.1A, an eligible entity can seek approval from its members, by way of a
special resolution passed at its annual general meeting, allowing the Company to have an
additional 10% capacity to issue securities for the relevant period.
An ‘eligible entity’ means an entity which is not included in the S&P/ASX 300 Index and which
has a market capitalisation of $300 million or less. Amplia Therapeutics Limited is an eligible
entity for these purposes.
Resolution 6 seeks Shareholder approval by way of special resolution for the Company to have
the additional 10% capacity provided for in Listing Rule 7.1A to issue Equity Securities without
Shareholder approval (10% Placement Facility).
If Resolution 6 is passed, the Company will be able to issue Equity Securities up to the
combined 25% limit in Listing Rules 7.1 and 7.1A without any further Shareholder approval.
If Resolution 6 is not passed, the Company will not be able to access the additional 10%
capacity to issue Equity Securities without Shareholder approval provided for in Listing Rule
7.1A and will remain s
Share your feedback
Discover